John M. Inadomi
No Rating Available
(Learn About Our Rating System)

John M. Inadomi, MD

Languages spoken: English

  • Dr. John Inadomi received an undergraduate degree in mechanical engineering from M.I.T. and an M.D. from the University of California, San Francisco (UCSF), where he completed his residency in internal medicine and fellowship in gastroenterology. He has been on the faculty of the University of New Mexico, the University of Michigan, UCSF, and the University of Washington where he served as the Division Head of Gastroenterology for 10 years. In 2020, Dr. Inadomi joined the University of Utah Health as the Jon M. Huntsman Presidential Chair and the Chair of the Department of Internal Medicine.

    Dr. Inadomi is a gastroenterologist with expertise in comparative effectiveness research. He has received funding from the National Institutes of Health (NIH) to evaluate new techniques to decrease mortality from esophageal adenocarcinoma, and to test novel interventions to increase adherence to colorectal cancer screening tests. He is an associate editor of Gastroenterology and is currently the President-Elect of the American Gastroenterological Association (AGA), and will become the President of the AGA in 2021.

    Specialties

    Board Certification

    American Board of Internal Medicine (Sub: Gastroenterology)
    American Board of Internal Medicine (Internal Medicine)

  • Dr. John Inadomi received an undergraduate degree in mechanical engineering from M.I.T. and an M.D. from the University of California, San Francisco (UCSF), where he completed his residency in internal medicine and fellowship in gastroenterology. He has been on the faculty of the University of New Mexico, the University of Michigan, UCSF, and the University of Washington where he served as the Division Head of Gastroenterology for 10 years. In 2020, Dr. Inadomi joined the University of Utah Health as the Jon M. Huntsman Presidential Chair and the Chair of the Department of Internal Medicine.

    Dr. Inadomi is a gastroenterologist with expertise in comparative effectiveness research. He has received funding from the National Institutes of Health (NIH) to evaluate new techniques to decrease mortality from esophageal adenocarcinoma, and to test novel interventions to increase adherence to colorectal cancer screening tests. He is an associate editor of Gastroenterology and is currently the President-Elect of the American Gastroenterological Association (AGA), and will become the President of the AGA in 2021.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Professor
    Academic Divisions Gastroenterology
    Board Certification
    American Board of Internal Medicine (Sub: Gastroenterology)
    American Board of Internal Medicine (Internal Medicine)

    Education history

    Undergraduate Mechanical Engineering - Massachusetts Institute of Technology S.B.
    Professional Medical Medicine - University of California, San Francisco M.D.
    Internship Internal Medicine - University of California, San Francisco Intern
    Residency Internal Medicine - University of California, San Francisco Resident
    Fellowship Gastroenterology - University of California, San Francisco Fellow

    Selected Publications

    Journal Article

    1. Inadomi JM, Sonnenberg A (1998). The impact of peptic ulcer disease and infection with Helicobacter pylori on life expectancy. Am J Gastroenterol, 93(8), 1286-90. (Read full publication)
    2. El-Serag HB, Lee P, Buchner A, Inadomi JM, Gavin M, McCarthy DM (2001). Lansoprazole treatment of patients with chronic idiopathic laryngitis: a placebo-controlled trial. Am J Gastroenterol, 96(4), 979-83. (Read full publication)
    3. Inadomi JM, McIntyre L, Bernard L, Fendrick AM (2003). Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs. Am J Gastroenterol, 98(9), 1940-4. (Read full publication)
    4. Rubenstein JH, Eisen GM, Inadomi JM (2004). A cost-utility analysis of secondary prophylaxis for variceal hemorrhage. Am J Gastroenterol, 99(7), 1274-88. (Read full publication)
    5. Chey WD, Inadomi JM, Booher AM, Sharma VK, Fendrick AM, Howden CW (2005). Primary-care physicians' perceptions and practices on the management of GERD: results of a national survey. Am J Gastroenterol, 100(6), 1237-42. (Read full publication)
    6. Rubenstein JH, Inadomi JM (2006). Evidence based medicine (EBM) in practice: applying results of cost-effectiveness analyses. Am J Gastroenterol, 101(6), 1169-71. (Read full publication)
    7. Heidelbaugh JJ, Inadomi JM (2006). Magnitude and economic impact of inappropriate use of stress ulcer prophylaxis in non-ICU hospitalized patients. Am J Gastroenterol, 101(10), 2200-5. (Read full publication)
    8. Metz DC, Inadomi JM, Howden CW, van Zanten SJ, Bytzer P (2007). On-demand therapy for gastroesophageal reflux disease. Am J Gastroenterol, 102(3), 642-53. (Read full publication)
    9. Rubenstein JH, Dahlkemper A, Kao JY, Zhang M, Morgenstern H, McMahon L, Inadomi JM (2008). A pilot study of the association of low plasma adiponectin and Barrett's esophagus. Am J Gastroenterol, 103(6), 1358-64. (Read full publication)
    10. Elmunzer BJ, Young SD, Inadomi JM, Schoenfeld P, Laine L (2008). Systematic review of the predictors of recurrent hemorrhage after endoscopic hemostatic therapy for bleeding peptic ulcers. Am J Gastroenterol, 103(10), 2625-32; quiz 2633. (Read full publication)
    11. Heidelbaugh JJ, Goldberg KL, Inadomi JM (2009). Overutilization of proton pump inhibitors: a review of cost-effectiveness and risk [corrected]. Am J Gastroenterol, 104 Suppl 2, S27-32. (Read full publication)
    12. Rex DK, Johnson DA, Anderson JC, Schoenfeld PS, Burke CA, Inadomi JM, American College of Gastroenterology. (2009). American College of Gastroenterology guidelines for colorectal cancer screening 2009 [corrected]. Am J Gastroenterol, 104(3), 739-50. (Read full publication)
    13. Rubenstein JH, Scheiman JM, Sadeghi S, Whiteman D, Inadomi JM (2011). Esophageal adenocarcinoma incidence in individuals with gastroesophageal reflux: synthesis and estimates from population studies. Am J Gastroenterol, 106(2), 254-60. (Read full publication)
    14. Rubenstein JH, Morgenstern H, Appelman H, Scheiman J, Schoenfeld P, McMahon LF Jr, Metko V, Near E, Kellenberg J, Kalish T, Inadomi JM (2013). Prediction of Barrett's esophagus among men. Am J Gastroenterol, 108(3), 353-62. (Read full publication)
    15. Kroep S, Lansdorp-Vogelaar I, Rubenstein JH, Lemmens VE, van Heijningen EB, Aragonés N, van Ballegooijen M, Inadomi JM (2014). Comparing trends in esophageal adenocarcinoma incidence and lifestyle factors between the United States, Spain, and the Netherlands. Am J Gastroenterol, 109(3), 336-43; quiz 335, 344. (Read full publication)
    16. Dimagno MJ, Wamsteker EJ, Rizk RS, Spaete JP, Gupta S, Sahay T, Costanzo J, Inadomi JM, Napolitano LM, Hyzy RC, Desmond JS (2014). A combined paging alert and web-based instrument alters clinician behavior and shortens hospital length of stay in acute pancreatitis. Am J Gastroenterol, 109(3), 306-15. (Read full publication)
    17. Park WG, Shaheen NJ, Cohen J, Pike IM, Adler DG, Inadomi JM, Laine LA, Lieb JG 2nd, Rizk MK, Sawhney MS, Wani S (2015). Quality indicators for EGD. Am J Gastroenterol, 110(1), 60-71. (Read full publication)
    18. Liang PS, Wheat CL, Abhat A, Brenner AT, Fagerlin A, Hayward RA, Thomas JP, Vijan S, Inadomi JM (2016). Adherence to Competing Strategies for Colorectal Cancer Screening Over 3 Years. Am J Gastroenterol, 111(1), 105-14. (Read full publication)
    19. Tramontano AC, Sheehan DF, Yeh JM, Kong CY, Dowling EC, Rubenstein JH, Abrams JA, Inadomi JM, Schrag D, Hur C (2017). The Impact of a Prior Diagnosis of Barrett's Esophagus on Esophageal Adenocarcinoma Survival. Am J Gastroenterol, 112(8), 1256-1264. (Read full publication)
    20. Rubenstein JH, Pohl H, Adams MA, Kerr E, Holleman R, Vijan S, Dominitz JA, Inadomi JM, Provenzale D, Francis J, Saini SD (2017). Overuse of Repeat Upper Endoscopy in the Veterans Health Administration: A Retrospective Analysis. Am J Gastroenterol, 112(11), 1678-1685. (Read full publication)
    21. Inadomi J, Koch J, Cello JP (1995). Long-term follow-up of endoscopic treatment for bleeding gastric and duodenal ulcers. Am J Gastroenterol, 90(7), 1065-8. (Read full publication)
    22. Vijan S, Hwang I, Inadomi J, Wong RK, Choi JR, Napierkowski J, Koff JM, Pickhardt PJ (2007). The cost-effectiveness of CT colonography in screening for colorectal neoplasia. Am J Gastroenterol, 102(2), 380-90. (Read full publication)
    23. Ho C, Kornfield R, Vittinghoff E, Inadomi J, Yee H, Somsouk M (2013). Late presentation of colorectal cancer in a vulnerable population. Am J Gastroenterol, 108(4), 466-70. (Read full publication)
    24. Bennett C, Moayyedi P, Corley DA, DeCaestecker J, Falck-Ytter Y, Falk G, Vakil N, Sanders S, Vieth M, Inadomi J, Aldulaimi D, Ho KY, Odze R, Meltzer SJ, Quigley E, Gittens S, Watson P, Zaninotto G, Iyer PG, Alexandre L, Ang Y, Callaghan J, Harrison R, Singh R, Bhandari P, Bisschops R, Geramizadeh B, Kaye P, Krishnadath S, Fennerty MB, Manner H, Nason KS, Pech O, Konda V, Ragunath K, Rahman I, Romero Y, Sampliner R, Siersema PD, Tack J, Tham TC, Trudgill N, Weinberg DS, Wang J, Wang K, Wong JY, Attwood S, Malfertheiner P, MacDonald D, Barr H, Ferguson MK, Jankowski J, BOB CAT Consortium. (2015). BOB CAT: A Large-Scale Review and Delphi Consensus for Management of Barrett's Esophagus With No Dysplasia, Indefinite for, or Low-Grade Dysplasia. Am J Gastroenterol, 110(5), 662-82; quiz 683. (Read full publication)
    25. Wani S, Muthusamy VR, Shaheen NJ, Yadlapati R, Wilson R, Abrams JA, Bergman J, Chak A, Chang K, Das A, Dumot J, Edmundowicz SA, Eisen G, Falk GW, Fennerty MB, Gerson L, Ginsberg GG, Grande D, Hall M, Harnke B, Inadomi J, Jankowski J, Lightdale CJ, Makker J, Odze RD, Pech O, Sampliner RE, Spechler S, Triadafilopoulos G, Wallace MB, Wang K, Waxman I, Komanduri S (2017). Development of Quality Indicators for Endoscopic Eradication Therapies in Barrett's Esophagus: The TREAT-BE (Treatment With Resection and Endoscopic Ablation Techniques for Barrett's Esophagus) Consortium. Am J Gastroenterol, 112(7), 1032-1048. (Read full publication)
    26. Inadomi J (2017). Editorial: Endoscopic Sedation: Who, Which, When?. The American journal of gastroenterology, 112(2), 303-305. (Read full publication)
    27. Ozanne EM, Silver ER, Saini SD, Rubenstein JH, Lansdorp-Vogelaar I, Bowers N, Tan SX, Inadomi JM, Hur (2021). Surveillance Cessation for Barrett's Esophagus: A Survey of Gastroenterologists. The American journal of gastroenterology, 116(8), 1730-1733. (Read full publication)
    28. El-Serag HB, Inadomi JM, Kowdley K (2000). Screening for hereditary hemochromatosis in siblings and children of affected patients. A cost-effectiveness analysis. Annals of internal medicine, 132(4), 261-9. (Read full publication)
    29. Sonnenberg A, Delcò F, Inadomi J (2000). Cost-effectiveness of colonoscopy in screening for colorectal cancer. Annals of internal medicine, 133(8), 573-84. (Read full publication)
    30. Inadomi JM, Sampliner R, Lagergren J, Lieberman D, Fendrick AM, Vakil (2003). Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis. Annals of internal medicine, 138(3), 176-86. (Read full publication)
    31. Sorrell MF, Belongia EA, Costa J, Gareen IF, Grem JL, Inadomi JM, Kern ER, McHugh JA, Petersen GM, Rein MF, Strader DB, Trotter H (2009). National Institutes of Health Consensus Development Conference Statement: management of hepatitis B. Annals of internal medicine, 150(2), 104-10. (Read full publication)
    32. Inadomi J, Alastal H, Bonavina L, Gross S, Hunt RH, Mashimo H, di Pietro M, Rhee H, Shah M, Tolone S, Wang DH, Xie S (2018). Recent advances in Barrett's esophagus. Annals of the New York Academy of Sciences, 1434(1), 227-238. (Read full publication)
    33. El-Serag HB, Graham DY, Richardson P, Inadomi J (2002). Prevention of complicated ulcer disease among chronic users of nonsteroidal anti-inflammatory drugs: the use of a nomogram in cost-effectiveness analysis. Archives of internal medicine, 162(18), 2105-10. (Read full publication)
    34. Inadomi JM, Vijan S, Janz NK, Fagerlin A, Thomas JP, Lin YV, Muñoz R, Lau C, Somsouk M, El-Nachef N, Hayward R (2012). Adherence to colorectal cancer screening: a randomized clinical trial of competing strategies. Archives of internal medicine, 172(7), 575-82. (Read full publication)
    35. Cram P, Fendrick AM, Inadomi J, Cowen ME, Carpenter D, Vijan (2003). The impact of a celebrity promotional campaign on the use of colon cancer screening: the Katie Couric effect. Archives of internal medicine, 163(13), 1601-5. (Read full publication)
    36. Tsui JI, Vittinghoff E, Shlipak MG, Bertenthal D, Inadomi J, Rodriguez RA, O'Hare A (2007). Association of hepatitis C seropositivity with increased risk for developing end-stage renal disease. Archives of internal medicine, 167(12), 1271-6. (Read full publication)
    37. Limoges-Gonzalez M, Mann NS, Al-Juburi A, Tseng D, Inadomi J, Rossaro (2011). Comparisons of screening colonoscopy performed by a nurse practitioner and gastroenterologists: a single-center randomized controlled trial. Gastroenterology nursing, 34(3), 210-6. (Read full publication)
    38. Brenner AT, Gupta S, Ko LK, Janz N, Inadomi J (2016). Development of a Practical Model for Targeting Patient Decision Support Interventions to Promote Colorectal Cancer Screening in Vulnerable Populations. Journal of health care for the poor and underserved, 27(2), 465-78. (Read full publication)
    39. Brenner AT, Ko LK, Janz N, Gupta S, Inadomi (2015). Race/Ethnicity and Primary Language: Health Beliefs about Colorectal Cancer Screening in a Diverse, Low-Income Population. Journal of health care for the poor and underserved, 26(3), 824-38. (Read full publication)
    40. Sonnenberg A, Inadomi J (1998). Review article: Medical decision models of Helicobacter pylori therapy to prevent gastric cancer. Alimentary pharmacology & therapeutics, 12 Suppl 1, 111-21. (Read full publication)
    41. Sonnenberg A, Inadomi JM, Becker L (1999). Economic analysis of step-wise treatment of gastro-oesophageal reflux disease. Alimentary pharmacology & therapeutics, 13(8), 1003-13. (Read full publication)
    42. Rubenstein JH, Vakil N, Inadomi J (2005). The cost-effectiveness of biomarkers for predicting the development of oesophageal adenocarcinoma. Alimentary pharmacology & therapeutics, 22(2), 135-46. (Read full publication)
    43. Rubenstein JH, Davis J, Marrero JA, Inadomi J (2005). Relationship between diabetes mellitus and adenocarcinoma of the oesophagus and gastric cardia. Alimentary pharmacology & therapeutics, 22(3), 267-71. (Read full publication)
    44. Chey WD, Eswaren S, Howden CW, Inadomi JM, Fendrick AM, Scheiman J (2006). Primary care physician perceptions of non-steroidal anti-inflammatory drug and aspirin-associated toxicity: results of a national survey. Alimentary pharmacology & therapeutics, 23(5), 655-68. (Read full publication)
    45. Rubenstein JH, Nojkov B, Korsnes S, Adlis SA, Shaw MJ, Weinman B, Inadomi JM, Saad R, Chey W (2007). Oesophageal hypersensitivity is associated with features of psychiatric disorders and the irritable bowel syndrome. Alimentary pharmacology & therapeutics, 26(3), 443-52. (Read full publication)
    46. Somsouk M, Guy J, Biggins SW, Vittinghoff E, Kohn MA, Inadomi J (2009). Ascites improves upon [corrected] serum sodium plus [corrected] model for end-stage liver disease (MELD) for predicting mortality in patients with advanced liver disease. Alimentary pharmacology & therapeutics, 30(7), 741-8. (Read full publication)
    47. Vijan S, Inadomi J, Hayward RA, Hofer TP, Fendrick A (2004). Projections of demand and capacity for colonoscopy related to increasing rates of colorectal cancer screening in the United States. Alimentary pharmacology & therapeutics, 20(5), 507-15. (Read full publication)
    48. Gunaratnam NT, Jessup TP, Inadomi J, Lascewski D (2006). Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease. Alimentary pharmacology & therapeutics, 23(10), 1473-7. (Read full publication)
    49. Inadomi JM, Fennerty MB, Bjorkman (2003). Systematic review: the economic impact of irritable bowel syndrome. Alimentary pharmacology & therapeutics, 18(7), 671-82. (Read full publication)
    50. Rutter CM, Johnson E, Miglioretti DL, Mandelson MT, Inadomi J, Buist D (2012). Adverse events after screening and follow-up colonoscopy. Cancer causes & control, 23(2), 289-96. (Read full publication)
    51. Inadomi J (2008). Taishotoyama Symposium Barriers to colorectal cancer screening: economics, capacity and adherence. Journal of gastroenterology and hepatology, 23 Suppl 2, S198-204. (Read full publication)
    52. Somsouk M, Estes JD, Deleage C, Dunham RM, Albright R, Inadomi JM, Martin JN, Deeks SG, McCune JM, Hunt P (2015). Gut epithelial barrier and systemic inflammation during chronic HIV infection. AIDS (London, England), 29(1), 43-51. (Read full publication)
    53. Gupta S, Brenner AT, Ratanawongsa N, Inadomi J (2014). Patient trust in physician influences colorectal cancer screening in low-income patients. American journal of preventive medicine, 47(4), 417-23. (Read full publication)
    54. Burnett-Hartman AN, Mehta SJ, Zheng Y, Ghai NR, McLerran DF, Chubak J, Quinn VP, Skinner CS, Corley DA, Inadomi JM, Doubeni CA, PROSPR Consortium (2016). Racial/Ethnic Disparities in Colorectal Cancer Screening Across Healthcare Systems. American journal of preventive medicine, 51(4), e107-15. (Read full publication)
    55. Biggins SW, Bambha K, Terrault N, Inadomi J, Roberts JP, Bass (2009). Transplant tourism to China: the impact on domestic patient-care decisions. Clinical transplantation, 23(6), 831-8. (Read full publication)
    56. Somsouk M, To'o K, Ali M, Vittinghoff E, Yeh BM, Yee J, Monto A, Inadomi JM, Aslam (2014). Esophageal varices on computed tomography and subsequent variceal hemorrhage. Abdominal imaging, 39(2), 251-6. (Read full publication)
    57. Kong CY, Kroep S, Curtius K, Hazelton WD, Jeon J, Meza R, Heberle CR, Miller MC, Choi SE, Lansdorp-Vogelaar I, van Ballegooijen M, Feuer EJ, Inadomi JM, Hur C, Luebeck E (2014). Exploring the recent trend in esophageal adenocarcinoma incidence and mortality using comparative simulation modeling. Cancer epidemiology, biomarkers & prevention, 23(6), 997-1006. (Read full publication)
    58. Hazelton WD, Curtius K, Inadomi JM, Vaughan TL, Meza R, Rubenstein JH, Hur C, Luebeck E (2015). The Role of Gastroesophageal Reflux and Other Factors during Progression to Esophageal Adenocarcinoma. Cancer epidemiology, biomarkers & prevention, 24(7), 1012-23. (Read full publication)
    59. Luebeck GE, Hazelton WD, Curtius K, Maden SK, Yu M, Carter KT, Burke W, Lampe PD, Li CI, Ulrich CM, Newcomb PA, Westerhoff M, Kaz AM, Luo Y, Inadomi JM, Grady W (2019). Implications of Epigenetic Drift in Colorectal Neoplasia. Cancer research, 79(3), 495-504. (Read full publication)
    60. Sonnenberg A, Inadomi J (1999). Economic perspectives in the management of Helicobacter pylori infections. Current topics in microbiology and immunology, 241, 237-60. (Read full publication)
    61. Sonnenberg A, Inadomi J (1999). Reliability block diagrams to model the management of colorectal cancer. Digestive diseases and sciences, 44(2), 314-21. (Read full publication)
    62. Somsouk M, Langfield DE, Inadomi JM, Yee HF J (2008). A cost-identification analysis of screening and surveillance of hepatitis C infection in a prospective cohort of dialysis patients. Digestive diseases and sciences, 53(4), 1093-9. (Read full publication)
    63. Sewell JL, Inadomi JM, Yee HF J (2010). Race and inflammatory bowel disease in an urban healthcare system. Digestive diseases and sciences, 55(12), 3479-87. (Read full publication)
    64. Inadomi JM, Saxena (2018). Screening and Surveillance for Barrett's Esophagus: Is It Cost-Effective?. Digestive diseases and sciences, 63(8), 2094-2104. (Read full publication)
    65. Zheng P, Kornfield R, Olmo C, Guy J, Inadomi J, Biggins S (2011). Reduced effectiveness of standard recruitment for deceased organ donor registration: the need for population-specific recruitment materials. Digestive diseases and sciences, 56(5), 1535-41. (Read full publication)
    66. Rubenstein JH, Morgenstern H, Kellenberg J, Kalish T, Donovan J, Inadomi J, McConnell D, Stojanovska J, Schoenfeld (2011). Validation of a new physical activity questionnaire for a sedentary population. Digestive diseases and sciences, 56(9), 2678-87. (Read full publication)
    67. Ende AR, De Groen P, Balmadrid BL, Hwang JH, Inadomi J, Wojtera T, Egorov V, Sarvazyan N, Korman (2018). Objective Differences in Colonoscopy Technique Between Trainee and Expert Endoscopists Using the Colonoscopy Force Monitor. Digestive diseases and sciences, 63(1), 46-52. (Read full publication)
    68. Day LW, Siao D, Inadomi JM, Somsouk (2014). Non-physician performance of lower and upper endoscopy: a systematic review and meta-analysis. Endoscopy, 46(5), 401-10. (Read full publication)
    69. Inadomi JM, Jamal R, Murata GH, Hoffman RM, Lavezo LA, Vigil JM, Swanson KM, Sonnenberg (2001). Step-down management of gastroesophageal reflux disease. Gastroenterology, 121(5), 1095-100. (Read full publication)
    70. Inadomi J (2007). Patients prefer conventional to virtual colonoscopy. Gastroenterology, 132(2), 809-11; discussion 811. (Read full publication)
    71. Inadomi JM, Somsouk M (2007). Proton pump inhibitors and hip fracture: cause for alarm?. Gastroenterology, 132(5), 2063-5; discussion 2065. (Read full publication)
    72. Cohen LB, Delegge MH, Aisenberg J, Brill JV, Inadomi JM, Kochman ML, Piorkowski JD Jr, AGA Institute (2007). AGA Institute review of endoscopic sedation. Gastroenterology, 133(2), 675-701. (Read full publication)
    73. Inadomi JM, Somsouk M (2007). Will virtual colonoscopy replace optical colonoscopy for colorectal cancer screening?. Gastroenterology, 133(4), 1384-5; discussion 1385-6. (Read full publication)
    74. Inadomi J (2008). Fear of loss, not promise of gain, drives practice patterns in Barrett's esophagus. Gastroenterology, 134(4), 1258-60; discussion 1260. (Read full publication)
    75. Inadomi JM, Somsouk M, Madanick RD, Thomas JP, Shaheen N (2009). A cost-utility analysis of ablative therapy for Barrett's esophagus. Gastroenterology, 136(7), 2101-2114.e1-6. (Read full publication)
    76. Dassopoulos T, Inadomi JM, Lewis JD, Allen J (2010). The development of clinical guidelines by the American Gastroenterological Association. Gastroenterology, 138(2), 417-8. (Read full publication)
    77. Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ, American Gastroenterological Association (2011). American Gastroenterological Association technical review on the management of Barrett's esophagus. Gastroenterology, 140(3), e18-52; quiz e13. (Read full publication)
    78. American Gastroenterological Association., Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen N (2011). American Gastroenterological Association medical position statement on the management of Barrett's esophagus. Gastroenterology, 140(3), 1084-91. (Read full publication)
    79. Hur C, Choi SE, Rubenstein JH, Kong CY, Nishioka NS, Provenzale DT, Inadomi J (2012). The cost effectiveness of radiofrequency ablation for Barrett's esophagus. Gastroenterology, 143(3), 567-575. (Read full publication)
    80. Rubenstein JH, Morgenstern H, McConell D, Scheiman JM, Schoenfeld P, Appelman H, McMahon LF Jr, Kao JY, Metko V, Zhang M, Inadomi J (2013). Associations of diabetes mellitus, insulin, leptin, and ghrelin with gastroesophageal reflux and Barrett's esophagus. Gastroenterology, 145(6), 1237-44.e1-5. (Read full publication)
    81. Dassopoulos T, Sultan S, Falck-Ytter YT, Inadomi JM, Hanauer S (2013). American Gastroenterological Association Institute technical review on the use of thiopurines, methotrexate, and anti-TNF-¿ biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease. Gastroenterology, 145(6), 1464-78.e1-5. (Read full publication)
    82. Kroep S, Lansdorp-Vogelaar I, Rubenstein JH, de Koning HJ, Meester R, Inadomi JM, van Ballegooijen (2015). An Accurate Cancer Incidence in Barrett's Esophagus: A Best Estimate Using Published Data and Modeling. Gastroenterology, 149(3), 577-85.e4; quiz e14-5. (Read full publication)
    83. Sharma P, Katzka DA, Gupta N, Ajani J, Buttar N, Chak A, Corley D, El-Serag H, Falk GW, Fitzgerald R, Goldblum J, Gress F, Ilson DH, Inadomi JM, Kuipers EJ, Lynch JP, McKeon F, Metz D, Pasricha PJ, Pech O, Peek R, Peters JH, Repici A, Seewald S, Shaheen NJ, Souza RF, Spechler SJ, Vennalaganti P, Wang (2015). Quality indicators for the management of Barrett's esophagus, dysplasia, and esophageal adenocarcinoma: international consensus recommendations from the American Gastroenterological Association Symposium. Gastroenterology, 149(6), 1599-606. (Read full publication)
    84. Wernli KJ, Brenner AT, Rutter CM, Inadomi J (2016). Risks Associated With Anesthesia Services During Colonoscopy. Gastroenterology, 150(4), 888-94; quiz e18. (Read full publication)
    85. Katzka DA, Friedman LS, Inadomi JM, Kalloo AM, Kim LS, Koch J, Lieberman D, Lichtenstein GR, Lim JK, Pandolfino JE, Shin AS, Siedler M (2016). Introduction to Clinical Practice Update Committee Articles. Gastroenterology, 151(1), 45. (Read full publication)
    86. Codipilly DC, Chandar AK, Singh S, Wani S, Shaheen NJ, Inadomi JM, Chak A, Iyer P (2018). The Effect of Endoscopic Surveillance in Patients With Barrett's Esophagus: A Systematic Review and Meta-analysis. Gastroenterology, 154(8), 2068-2086.e5. (Read full publication)
    87. Inadomi J, Sonnenberg (1997). Cost-analysis of prophylactic antibiotics in spontaneous bacterial peritonitis. Gastroenterology, 113(4), 1289-94. (Read full publication)
    88. Ladabaum U, Brill JV, Sonnenberg A, Shaheen NJ, Inadomi J, Wilcox CM, Park WG, Hur C, Pasricha P (2013). How to value technological innovation: a proposal for determining relative clinical value. Gastroenterology, 144(1), 5-8. (Read full publication)
    89. Inadomi JM, Weinberg D (2013). How to recognize a good guideline. Gastroenterology, 145(6), 1179-81. (Read full publication)
    90. Sultan S, Siddique SM, Altayar O, Caliendo AM, Davitkov P, Feuerstein JD, Francis D, Inadomi JM, Lim JK, Falck-Ytter Y, Mustafa RA, American Gastroenterological Association. Electronic address: ewilson@gastro.org (2020). AGA Institute Rapid Review and Recommendations on the Role of Pre-Procedure SARS-CoV-2 Testing and Endoscopy. Gastroenterology, 159(5), 1935-1948.e5. (Read full publication)
    91. Omidvari AH, Hazelton WD, Lauren BN, Naber SK, Lee M, Ali A, Seguin C, Kong CY, Richmond E, Rubenstein JH, Luebeck GE, Inadomi JM, Hur C, Lansdorp-Vogelaar (2021). The Optimal Age to Stop Endoscopic Surveillance of Patients With Barrett's Esophagus Based on Sex and Comorbidity: A Comparative Cost-Effectiveness Analysis. Gastroenterology, 161(2), 487-494.e4. (Read full publication)
    92. Sultan S, Siddique SM, Singh S, Altayar O, Caliendo AM, Davitkov P, Feuerstein JD, Kaul V, Lim JK, Mustafa RA, Falck-Ytter Y, Inadomi JM, American Gastroenterological Association (2021). AGA Rapid Review and Guideline for SARS-CoV2 Testing and Endoscopy Post-Vaccination: 2021 Update. Gastroenterology, (Read full publication)
    93. Inadomi JM, Sonnenberg (2000). The impact of colorectal cancer screening on life expectancy. Gastrointestinal endoscopy, 51(5), 517-23. (Read full publication)
    94. Menees SB, Inadomi JM, Korsnes S, Elta G (2005). Women patients' preference for women physicians is a barrier to colon cancer screening. Gastrointestinal endoscopy, 62(2), 219-23. (Read full publication)
    95. Inadomi J (2006). Implementing a research project: the nitty gritty. Gastrointestinal endoscopy, 64(6 Suppl), S7-10. (Read full publication)
    96. Kudo Se, Lambert R, Allen JI, Fujii H, Fujii T, Kashida H, Matsuda T, Mori M, Saito H, Shimoda T, Tanaka S, Watanabe H, Sung JJ, Feld AD, Inadomi JM, O'Brien MJ, Lieberman DA, Ransohoff DF, Soetikno RM, Triadafilopoulos G, Zauber A, Teixeira CR, Rey JF, Jaramillo E, Rubio CA, Van Gossum A, Jung M, Vieth M, Jass JR, Hurlstone P (2008). Nonpolypoid neoplastic lesions of the colorectal mucosa. Gastrointestinal endoscopy, 68(4 Suppl), S3-47. (Read full publication)
    97. Lambert R, Kudo SE, Vieth M, Allen JI, Fujii H, Fujii T, Kashida H, Matsuda T, Mori M, Saito H, Shimoda T, Tanaka S, Watanabe H, Sung JJ, Feld AD, Inadomi JM, O'Brien MJ, Lieberman DA, Ransohoff DF, Soetikno RM, Zauber A, Teixeira CR, Rey JF, Jaramillo E, Rubio CA, Van Gossum A, Jung M, Jass JR, Triadafilopoulos (2009). Pragmatic classification of superficial neoplastic colorectal lesions. Gastrointestinal endoscopy, 70(6), 1182-99. (Read full publication)
    98. Inadomi JM, Gunnarsson CL, Rizzo JA, Fang (2010). Projected increased growth rate of anesthesia professional-delivered sedation for colonoscopy and EGD in the United States: 2009 to 2015. Gastrointestinal endoscopy, 72(3), 580-6. (Read full publication)
    99. Day LW, Kwon A, Inadomi JM, Walter LC, Somsouk (2011). Adverse events in older patients undergoing colonoscopy: a systematic review and meta-analysis. Gastrointestinal endoscopy, 74(4), 885-96. (Read full publication)
    100. Elmunzer BJ, Singal AG, Sussman JB, Deshpande AR, Sussman DA, Conte ML, Dwamena BA, Rogers MA, Schoenfeld PS, Inadomi JM, Saini SD, Waljee A (2015). Comparing the effectiveness of competing tests for reducing colorectal cancer mortality: a network meta-analysis. Gastrointestinal endoscopy, 81(3), 700-709.e3. (Read full publication)
    101. Choi AY, Strate LL, Fix MC, Schmidt RA, Ende AR, Yeh MM, Inadomi JM, Hwang J (2018). Association of gastric intestinal metaplasia and East Asian ethnicity with the risk of gastric adenocarcinoma in a U.S. population. Gastrointestinal endoscopy, 87(4), 1023-1028. (Read full publication)
    102. Rhee J, Scheiman J, Inadomi (2003). "Spontaneous" passage of a pancreatic duct stone. Gastrointestinal endoscopy, 57(2), 278-80. (Read full publication)
    103. Rubenstein JH, Sonnenberg A, Davis J, McMahon L, Inadomi J (2008). Effect of a prior endoscopy on outcomes of esophageal adenocarcinoma among United States veterans. Gastrointestinal endoscopy, 68(5), 849-55. (Read full publication)
    104. Shergill AK, Conners EE, McQuaid KR, Epstein S, Ryan JC, Shah JN, Inadomi J, Somsouk (2015). Protective association of colonoscopy against proximal and distal colon cancer and patterns in interval cancer. Gastrointestinal endoscopy, 82(3), 529-37.e1. (Read full publication)
    105. Park WG, Shaheen NJ, Cohen J, Pike IM, Adler DG, Inadomi JM, Laine LA, Lieb JG 2nd, Rizk MK, Sawhney MS, Wani (2015). Quality indicators for EGD. Gastrointestinal endoscopy, 81(1), 17-30. (Read full publication)
    106. El-Serag HB, Sonnenberg A, Jamal MM, Inadomi JM, Crooks LA, Feddersen R (1999). Corpus gastritis is protective against reflux oesophagitis. Gut, 45(2), 181-5. (Read full publication)
    107. Shaheen NJ, Inadomi JM, Overholt BF, Sharma (2004). What is the best management strategy for high grade dysplasia in Barrett's oesophagus? A cost effectiveness analysis. Gut, 53(12), 1736-44. (Read full publication)
    108. Rubenstein JH, Morgenstern H, Chey WD, Murray J, Scheiman JM, Schoenfeld P, Appelman HD, McMahon L, Metko V, Kellenberg J, Kalish T, Baker J, Inadomi J (2014). Protective role of gluteofemoral obesity in erosive oesophagitis and Barrett's oesophagus. Gut, 63(2), 230-5. (Read full publication)
    109. Senore C, Inadomi J, Segnan N, Bellisario C, Hassan (2015). Optimising colorectal cancer screening acceptance: a review. Gut, 64(7), 1158-77. (Read full publication)
    110. Curtius K, Rubenstein JH, Chak A, Inadomi J (2020). Computational modelling suggests that Barrett's oesophagus may be the precursor of all oesophageal adenocarcinomas. Gut, (Read full publication)
    111. Sorrell MF, Belongia EA, Costa J, Gareen IF, Grem JL, Inadomi JM, Kern ER, McHugh JA, Petersen GM, Rein MF, Strader DB, Trotter H (2009). National Institutes of Health consensus development conference statement: management of hepatitis B. Hepatology (Baltimore, Md.), 49(5 Suppl), S4-S12. (Read full publication)
    112. Inadomi J, Cello JP, Koch (1996). Ultrasonographic determination of ascitic volume. Hepatology (Baltimore, Md.), 24(3), 549-51. (Read full publication)
    113. Day LW, Cello JP, Somsouk M, Inadomi J (2011). Prevalence of gastric cancer versus colorectal cancer in Asians with a positive fecal occult blood test. Indian journal of gastroenterology, 30(5), 209-16. (Read full publication)
    114. Gorelick AB, Inadomi JM, Barnett J (2001). Unsedated small-caliber esophagogastroduodenoscopy (EGD): less expensive and less time-consuming than conventional EGD. Journal of clinical gastroenterology, 33(3), 210-4. (Read full publication)
    115. Rubenstein JH, Inadomi J (2006). Defining a clinically significant adverse impact of diagnosing Barrett's esophagus. Journal of clinical gastroenterology, 40(2), 109-15. (Read full publication)
    116. Elmunzer BJ, Inadomi JM, Elta G (2007). Risk stratification in upper gastrointestinal bleeding. Journal of clinical gastroenterology, 41(6), 559-63. (Read full publication)
    117. Sewell JL, Kushel MB, Inadomi JM, Yee HF J (2009). Non-English speakers attend gastroenterology clinic appointments at higher rates than English speakers in a vulnerable patient population. Journal of clinical gastroenterology, 43(7), 652-60. (Read full publication)
    118. Miegel RE, Walker PS, Nelson PC, Inadomi J, Needelman L, Maxine (1986). A compliant interface for total knee arthroplasty. Journal of orthopaedic research, 4(4), 486-93. (Read full publication)
    119. Lieberman D, Ladabaum U, Cruz-Correa M, Ginsburg C, Inadomi JM, Kim LS, Giardiello FM, Wender R (2016). Screening for Colorectal Cancer and Evolving Issues for Physicians and Patients: A Review. JAMA, 316(20), 2135-2145. (Read full publication)
    120. Inadomi J (2009). Surveillance in Barrett's esophagus: a failed premise. The Keio journal of medicine, 58(1), 12-8. (Read full publication)
    121. Sonnenberg A, Inadomi JM, Bauerfeind (1999). Reliability block diagrams to model disease management. Medical decision making, 19(2), 180-5. (Read full publication)
    122. Kroep S, Lansdorp-Vogelaar I, van der Steen A, Inadomi JM, van Ballegooijen (2015). The Impact of Uncertainty in Barrett's Esophagus Progression Rates on Hypothetical Screening and Treatment Decisions. Medical decision making, 35(6), 726-33. (Read full publication)
    123. Inadomi J (2017). Screening for Colorectal Neoplasia. The New England journal of medicine, 376(2), 149-156. (Read full publication)
    124. Ritvo P, Myers RE, Serenity M, Gupta S, Inadomi JM, Green BB, Jerant A, Tinmouth J, Paszat L, Pirbaglou M, Rabeneck (2017). Taxonomy for colorectal cancer screening promotion: Lessons from recent randomized controlled trials. Preventive medicine, 101, 229-234. (Read full publication)
    125. Croswell JM, Corley DA, Lafata JE, Haas JS, Inadomi JM, Kamineni A, Ritzwoller DP, Vachani A, Zheng Y, National Cancer Institute Population-based Research to Optimize the Screening Process (PROSPR) II Consortium (2021). Cancer screening in the U.S. through the COVID-19 pandemic, recovery, and beyond. Preventive medicine, 151, 106595. (Read full publication)
    126. Inadomi J (2003). Cost-effectiveness of colorectal cancer surveillance in ulcerative colitis. Scandinavian journal of gastroenterology. Supplement, (237), 17-21. (Read full publication)
    127. Brown LM, Rogers SJ, Cello JP, Brasel KJ, Inadomi J (2011). Cost-effective treatment of patients with symptomatic cholelithiasis and possible common bile duct stones. Journal of the American College of Surgeons, 212(6), 1049-1060.e1-7. (Read full publication)
    128. Inadomi J (2004). Decision analysis and economic modelling: a primer. European journal of gastroenterology & hepatology, 16(6), 535-42. (Read full publication)
    129. Suzuki H, Inadomi JM, Hibi (2009). Japanese herbal medicine in functional gastrointestinal disorders. Neurogastroenterology and motility, 21(7), 688-96. (Read full publication)
    130. Matsuzaki J, Suzuki H, Asakura K, Fukushima Y, Inadomi JM, Takebayashi T, Hibi (2012). Classification of functional dyspepsia based on concomitant bowel symptoms. Neurogastroenterology and motility, 24(4), 325-e164. (Read full publication)
    131. Suzuki H, Matsuzaki J, Masaoka T, Inadomi J (2014). Greater loss of productivity among Japanese workers with gastro-esophageal reflux disease (GERD) symptoms that persist vs resolve on medical therapy. Neurogastroenterology and motility, 26(6), 764-71. (Read full publication)
    132. Inadomi JM, Kapur S, Kinkhabwala M, Cello J (2001). The laparoscopic evaluation of ascites. Gastrointestinal endoscopy clinics of North America, 11(1), 79-91. (Read full publication)
    133. Saxena N, Inadomi J (2017). Effectiveness and Cost-Effectiveness of Endoscopic Screening and Surveillance. Gastrointestinal endoscopy clinics of North America, 27(3), 397-421. (Read full publication)
    134. Rubenstein JH, Inadomi J (2021). Cost-Effectiveness of Screening, Surveillance, and Endoscopic Eradication Therapies for Managing the Burden of Esophageal Adenocarcinoma. Gastrointestinal endoscopy clinics of North America, 31(1), 77-90. (Read full publication)
    135. Inadomi J (2003). Update on the cost-effectiveness of screening for colorectal neoplasia. Current opinion in gastroenterology, 19(1), 44-50. (Read full publication)
    136. Sewell JL, Yee HF Jr, Inadomi J (2010). Hospitalizations are increasing among minority patients with Crohn's disease and ulcerative colitis. Inflammatory bowel diseases, 16(2), 204-7. (Read full publication)
    137. Inadomi J (2002). On-demand and intermittent therapy for gastro-oesophageal reflux disease: economic considerations. PharmacoEconomics, 20(9), 565-76. (Read full publication)
    138. Heidelbaugh JJ, Goldberg KL, Inadomi J (2010). Magnitude and economic effect of overuse of antisecretory therapy in the ambulatory care setting. The American journal of managed care, 16(9), e228-34. (Read full publication)
    139. Somsouk M, Kornfield R, Vittinghoff E, Inadomi JM, Biggins S (2011). Moderate ascites identifies patients with low model for end-stage liver disease scores awaiting liver transplantation who have a high mortality risk. Liver transplantation, 17(2), 129-36. (Read full publication)
    140. Biggins SW, Bambha KM, Terrault NA, Inadomi J, Shiboski S, Dodge JL, Gralla J, Rosen HR, Roberts J (2012). Projected future increase in aging hepatitis C virus-infected liver transplant candidates: a potential effect of hepatocellular carcinoma. Liver transplantation, 18(12), 1471-8. (Read full publication)
    141. Horibe M, Kaneko T, Yokogawa N, Yokota T, Okawa O, Nakatani Y, Ogura Y, Matsuzaki J, Iwasaki E, Hosoe N, Masaoka T, Inadomi JM, Suzuki H, Kanai T, Namiki (2016). A simple scoring system to assess the need for an endoscopic intervention in suspected upper gastrointestinal bleeding: A prospective cohort study. Digestive and liver disease, 48(10), 1180-6. (Read full publication)
    142. Ko LK, Taylor VM, Yoon J, Copeland WK, Hwang JH, Lee EJ, Inadomi (2016). The impact of medical tourism on colorectal screening among Korean Americans: A community-based cross-sectional study. BMC cancer, 16(1), 931. (Read full publication)
    143. Inadomi J (2015). Cost considerations in implementing a screening and surveillance strategy for Barrett's oesophagus. Best practice & research. Clinical gastroenterology, 29(1), 51-63. (Read full publication)
    144. Buxbaum JL, Biggins SW, Bagatelos KC, Inadomi JM, Ostroff J (2011). Inoperable pancreatic cancer patients who have prolonged survival exhibit an increased risk of cholangitis. JOP, 12(4), 377-83. (Read full publication)
    145. Biggins SW, Gralla J, Dodge JL, Bambha KM, Tong S, Barón AE, Inadomi J, Terrault N, Rosen H (2014). Survival benefit of repeat liver transplantation in the United States: a serial MELD analysis by hepatitis C status and donor risk index. American journal of transplantation, 14(11), 2588-94. (Read full publication)
    146. Menees SB, Inadomi J, Elta G, Korsnes S, Punch M, Aldrich (2010). Colorectal cancer screening compliance and contemplation in gynecology patients. Journal of women's health (2002), 19(5), 911-7. (Read full publication)
    147. Taylor VM, Ko LK, Hwang JH, Sin MK, Inadomi J (2014). Gastric cancer in asian american populations: a neglected health disparity. Asian Pacific journal of cancer prevention, 15(24), 10565-71. (Read full publication)
    148. Inadomi JM, Sonnenberg (2003). An evidence-based medicine approach to economic studies: assessing the cost-effectiveness of competing strategies for colorectal cancer screening. Clinical gastroenterology and hepatology, 1(5), 404-13. (Read full publication)
    149. Inadomi JM, Fendrick A (2005). PPI use in the OTC era: who to treat, with what, and for how long?. Clinical gastroenterology and hepatology, 3(3), 208-15. (Read full publication)
    150. Rubenstein JH, Inadomi JM, Brill JV, Eisen G (2007). Cost utility of screening for Barrett's esophagus with esophageal capsule endoscopy versus conventional upper endoscopy. Clinical gastroenterology and hepatology, 5(3), 312-8. (Read full publication)
    151. Somsouk M, Gralnek IM, Inadomi J (2008). Management of obscure occult gastrointestinal bleeding: a cost-minimization analysis. Clinical gastroenterology and hepatology, 6(6), 661-70. (Read full publication)
    152. Guy J, Somsouk M, Shiboski S, Kerlan R, Inadomi JM, Biggins S (2009). New model for end stage liver disease improves prognostic capability after transjugular intrahepatic portosystemic shunt. Clinical gastroenterology and hepatology, 7(11), 1236-40. (Read full publication)
    153. Sultan S, Falck-Ytter Y, Inadomi J (2013). The AGA institute process for developing clinical practice guidelines part one: grading the evidence. Clinical gastroenterology and hepatology, 11(4), 329-32. (Read full publication)
    154. Rubenstein JH, Inadomi JM, Scheiman J, Schoenfeld P, Appelman H, Zhang M, Metko V, Kao J (2014). Association between Helicobacter pylori and Barrett's esophagus, erosive esophagitis, and gastroesophageal reflux symptoms. Clinical gastroenterology and hepatology, 12(2), 239-45. (Read full publication)
    155. Johnson DA, Lieberman D, Inadomi JM, Ladabaum U, Becker RC, Gross SA, Hood KL, Kushins S, Pochapin M, Robertson D (2017). Increased Post-procedural Non-gastrointestinal Adverse Events After Outpatient Colonoscopy in High-risk Patients. Clinical gastroenterology and hepatology, 15(6), 883-891.e9. (Read full publication)
    156. Heberle CR, Omidvari AH, Ali A, Kroep S, Kong CY, Inadomi JM, Rubenstein JH, Tramontano AC, Dowling EC, Hazelton WD, Luebeck EG, Lansdorp-Vogelaar I, Hur (2017). Cost Effectiveness of Screening Patients With Gastroesophageal Reflux Disease for Barrett's Esophagus With a Minimally Invasive Cell Sampling Device. Clinical gastroenterology and hepatology, 15(9), 1397-1404.e7. (Read full publication)
    157. Kroep S, Heberle CR, Curtius K, Kong CY, Lansdorp-Vogelaar I, Ali A, Wolf WA, Shaheen NJ, Spechler SJ, Rubenstein JH, Nishioka NS, Meltzer SJ, Hazelton WD, van Ballegooijen M, Tramontano AC, Gazelle GS, Luebeck EG, Inadomi JM, Hur (2017). Radiofrequency Ablation of Barrett's Esophagus Reduces Esophageal Adenocarcinoma Incidence and Mortality in a Comparative Modeling Analysis. Clinical gastroenterology and hepatology, 15(9), 1471-1474. (Read full publication)
    158. Chu JN, Choi J, Tramontano A, Morse C, Forcione D, Nishioka NS, Abrams JA, Rubenstein JH, Kong CY, Inadomi JM, Hur (2018). Surgical vs Endoscopic Management of T1 Esophageal Adenocarcinoma: A Modeling Decision Analysis. Clinical gastroenterology and hepatology, 16(3), 392-400.e7. (Read full publication)
    159. Inadomi JM, Issaka RB, Green B (2019). What Multilevel Interventions Do We Need to Increase the Colorectal Cancer Screening Rate to 80%?. Clinical gastroenterology and hepatology, (Read full publication)
    160. Fass R, Inadomi J, Han C, Mody R, O'Neil J, Perez M (2012). Maintenance of heartburn relief after step-down from twice-daily proton pump inhibitor to once-daily dexlansoprazole modified release. Clinical gastroenterology and hepatology, 10(3), 247-53. (Read full publication)
    161. Singal AG, Gupta S, Lee J, Halm EA, Rutter CM, Corley D, Inadomi (2014). Importance of determining indication for colonoscopy: implications for practice and policy original. Clinical gastroenterology and hepatology, 12(12), 1958-63.e1-3. (Read full publication)
    162. Omidvari AH, Ali A, Hazelton WD, Kroep S, Lee M, Naber SK, Lauren BN, Ostvar S, Richmond E, Kong CY, Rubenstein JH, Lansdorp-Vogelaar I, Luebeck G, Hur C, Inadomi (2019). Optimizing Management of Patients with Barrett's Esophagus and Low-grade or No Dysplasia Based On Comparative Modeling: Optimizing Barrett's esophagus management. Clinical gastroenterology and hepatology, (Read full publication)
    163. Matsuzaki J, Suzuki H, Kobayakawa M, Inadomi JM, Takayama M, Makino K, Iwao Y, Sugino Y, Kanai (2015). Association of Visceral Fat Area, Smoking, and Alcohol Consumption with Reflux Esophagitis and Barrett's Esophagus in Japan. PloS one, 10(7), e0133865. (Read full publication)
    164. Day LW, Bhuket T, Inadomi JM, Yee H (2013). Diversity of endoscopy center operations and practice variation across California's safety-net hospital system: a statewide survey. BMC research notes, 6, 233. (Read full publication)
    165. Inadomi (2010). Issues Related to BID Dosing of PPIs. Gastroenterology & hepatology, 6(6), 369-70. (Read full publication)
    166. Inadomi J (2009). Updates in colorectal cancer screening. F1000 medicine reports, 1, (Read full publication)
    167. Issaka RB, Akinsoto NO, Strait E, Chaudhari V, Flum DR, Inadomi J (2020). Effectiveness of a mailed fecal immunochemical test outreach: a Medicare Advantage pilot study. Therapeutic advances in gastroenterology, 13, 1756284820945388. (Read full publication)
    168. Rubenstein JH, Tavakkoli A, Koeppe E, Ulintz P, Inadomi JM, Morgenstern H, Appelman H, Scheiman JM, Schoenfeld P, Metko V, Stoffel E (2020). Family History of Colorectal or Esophageal Cancer in Barrett's Esophagus and Potentially Explanatory Genetic Variants. Clinical and translational gastroenterology, 11(4), e00151. (Read full publication)
    169. Rastogi N, Xia Y, Inadomi JM, Kwon SC, Trinh-Shevrin C, Liang P (2019). Disparities in colorectal cancer screening in New York City: An analysis of the 2014 NYC Community Health Survey. Cancer medicine, 8(5), 2572-2579. (Read full publication)
    170. Wernli KJ, Inadomi J (2013). Anesthesia for colonoscopy: too much of a good thing?. JAMA internal medicine, 173(7), 556-8. (Read full publication)
    171. Snider EJ, Kaz AM, Inadomi JM, Grady W (2020). Chemoprevention of esophageal adenocarcinoma. Gastroenterology report, 8(4), 253-260. (Read full publication)
    172. Issaka RB, Li L, Fedorenko C, Ko CW, Inadomi JM, Ramsey S (2020). Racial Disparities in Colorectal Cancer Mortality: the Role of Endoscopy Wait-Time and Stage at Diagnosis. Journal of racial and ethnic health disparities, 7(5), 967-974. (Read full publication)
    173. Burnett-Hartman AN, Kamineni A, Corley DA, Singal AG, Halm EA, Rutter CM, Chubak J, Lee JK, Doubeni CA, Inadomi JM, Doria-Rose VP, Zheng (2019). Colonoscopy Indication Algorithm Performance Across Diverse Health Care Systems in the PROSPR Consortium. EGEMS (Washington, DC), 7(1), 37. (Read full publication)
    174. Inadomi JM, Saxena (2018). Endoscopic surveillance or ablation for Barrett's esophagus?. Translational gastroenterology and hepatology, 3, 102. (Read full publication)
    175. ASGE Endoscopy Unit Quality Indicator Taskforce., Day LW, Cohen J, Greenwald D, Petersen BT, Schlossberg NS, Vicari JJ, Calderwood AH, Chapman FJ, Cohen LB, Eisen G, Gerstenberger PD, Hambrick RD 3rd, Inadomi JM, MacIntosh D, Sewell JL, Valori (2017). Quality indicators for gastrointestinal endoscopy units. VideoGIE, 2(6), 119-140. (Read full publication)
    176. Issaka RB, Inadomi J (2018). Low-Value Colorectal Cancer Screening: Too Much of a Good Thing?. JAMA network open, 1(8), e185445. (Read full publication)
    177. Issaka RB, Taylor P, Baxi A, Inadomi JM, Ramsey SD, Roth (2021). Model-Based Estimation of Colorectal Cancer Screening and Outcomes During the COVID-19 Pandemic. JAMA network open, 4(4), e216454. (Read full publication)
    178. Issaka RB, Bell-Brown A, Snyder C, Atkins DL, Chew L, Weiner BJ, Strate L, Inadomi JM, Ramsey S (2021). Perceptions on Barriers and Facilitators to Colonoscopy Completion After Abnormal Fecal Immunochemical Test Results in a Safety Net System. JAMA network open, 4(8), e2120159. (Read full publication)

    Conference Proceedings

    1. Bennett C, Vakil N, Bergman J, Harrison R, Odze R, Vieth M, Sanders S, Gay L, Pech O, Longcroft-Wheaton G, Romero Y, Inadomi J, Tack J, Corley DA, Manner H, Green S, Al Dulaimi D, Ali H, Allum B, Anderson M, Curtis H, Falk G, Fennerty MB, Fullarton G, Krishnadath K, Meltzer SJ, Armstrong D, Ganz R, Cengia G, Going JJ, Goldblum J, Gordon C, Grabsch H, Haigh C, Hongo M, Johnston D, Forbes-Young R, Kay E, Kaye P, Lerut T, Lovat LB, Lundell L, Mairs P, Shimoda T, Spechler S, Sontag S, Malfertheiner P, Murray I, Nanji M, Poller D, Ragunath K, Regula J, Cestari R, Shepherd N, Singh R, Stein HJ, Talley NJ, Galmiche JP, Tham TC, Watson P, Yerian L, Rugge M, Rice TW, Hart J, Gittens S, Hewin D, Hochberger J, Kahrilas P, Preston S, Sampliner R, Sharma P, Stuart R, Wang K, Waxman I, Abley C, Loft D, Penman I, Shaheen NJ, Chak A, Davies G, Dunn L, Falck-Ytter Y, Decaestecker J, Bhandari P, Ell C, Griffin SM, Attwood S, Barr H, Allen J, Ferguson MK, Moayyedi P, Jankowski J (2012). Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology, 143(2), 336-46. (Read full publication)
    2. Wani S, Muthusamy VR, Shaheen NJ, Yadlapati R, Wilson R, Abrams JA, Bergman J, Chak A, Chang K, Das A, Dumot J, Edmundowicz SA, Eisen G, Falk GW, Fennerty MB, Gerson L, Ginsberg GG, Grande D, Hall M, Harnke B, Inadomi J, Jankowski J, Lightdale CJ, Makker J, Odze RD, Pech O, Sampliner RE, Spechler S, Triadafilopoulos G, Wallace MB, Wang K, Waxman I, Komanduri (2017). Development of quality indicators for endoscopic eradication therapies in Barrett's esophagus: the TREAT-BE (Treatment with Resection and Endoscopic Ablation Techniques for Barrett's Esophagus) Consortium. Gastrointestinal endoscopy, 86(1), 1-17.e3. (Read full publication)
    3. Rimola A, García-Tsao G, Navasa M, Piddock LJ, Planas R, Bernard B, Inadomi J (2000). Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club. Journal of hepatology, 32(1), 142-53. (Read full publication)

    Editorial

    1. Inadomi (2010). Editorial: Interval cancers after colonoscopy: the importance of training. The American journal of gastroenterology, 105(12), 2597-8. (Read full publication)
    2. Bibbins-Domingo K, Inadomi (2018). Why "More Research Is Needed," Despite Overall Certainty: Women and Colorectal Cancer Screening. Annals of internal medicine, 168(11), 824-825. (Read full publication)
    3. Inadomi J (2008). In search of quality colonoscopy. Gastroenterology, 135(6), 1845-7. (Read full publication)
    4. Inadomi J (2011). Time to burn? Endoscopic ablation for Barrett's esophagus. Gastroenterology, 141(2), 417-9. (Read full publication)
    5. Inadomi J (2012). Is 325 mg of prevention worth a pound of cure?. Gastroenterology, 143(4), 885-7. (Read full publication)
    6. Inadomi J (2020). What's App with GERD?. Gastroenterology, 158(5), 1211-1212. (Read full publication)
    7. Rubenstein JH, Inadomi J (2005). Dysphagia drives doctors to diagnose a disease: pitfalls in interpreting observational studies. Gastrointestinal endoscopy, 61(7), 809-11. (Read full publication)
    8. Rubenstein JH, Inadomi J (2003). Empiric beta-blockers for the prophylaxis of variceal hemorrhage: cost effective or clinically applicable?. Hepatology (Baltimore, Md.), 37(2), 249-52. (Read full publication)
    9. Rutter CM, Inadomi J (2017). Follow-up of Positive Fecal Test Results: Sooner Is Better, but How Much Better?. JAMA, 317(16), 1627-1628. (Read full publication)
    10. Inadomi J (2012). Why you should care about screening flexible sigmoidoscopy. The New England journal of medicine, 366(25), 2421-2. (Read full publication)
    11. Inadomi JM, Terdiman (2006). Exploring utilities and outcomes with infliximab therapy. Clinical gastroenterology and hepatology, 4(8), 976-8. (Read full publication)
    12. Friedman LS, Inadomi JM, Kalloo AM, Katzka DA, Kim LS, Koch J, Lieberman D, Lichtenstein GR, Lim JK, Pandolfino JE, Shin AS, Siedler M (2017). Introduction of Clinical Practice Update Committee Articles. Clinical gastroenterology and hepatology, 15(1), 4. (Read full publication)
    13. Inadomi J (2016). Colorectal Cancer Screening: Which Test Is Best?. JAMA oncology, 2(8), 1001-3. (Read full publication)

    Letter

    1. Rubenstein JH, Inadomi JM (2009). Potential for lead-time and length-time biases in outcomes in esophageal adenocarcinoma. [Letter to the editor]. Am J Gastroenterol, 104(12), 3106-7; author reply 3107-8. (Read full publication)
    2. Wernli KJ, Brenner AT, Rutter CM, Inadomi J (2016). Reply. Gastroenterology, 151(3), 564. (Read full publication)
    3. Rutter CM, Inadomi J (2017). Time to Diagnostic Testing After a Positive Colorectal Cancer Screening Test-Reply. JAMA, 318(5), 483-484. (Read full publication)
    4. Inadomi J (2017). Screening for Colorectal Neoplasia. The New England journal of medicine, 376(16), 1599-1600. (Read full publication)

    Newspaper

    1. Inadomi J (2021). Should all patients be tested for SARS-CoV-2 before endoscopy?.

    Other

    1. Chiba N, Gralnek IM, Moayyedi P, Provenzale D, Inadomi JM, Willan AR, Briggs AH, Kim W (2004). A glossary of economic terms. European journal of gastroenterology & hepatology, 16(6), 563-5. (Read full publication)

  • News & Podcasts

    News